The Latest Cardiac and Vascular News
SUNNYVALE, Calif., Oct. 25, 2023 /PRNewswire/ — EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy (CRT) in the United States…
SAN FRANCISCO–(BUSINESS WIRE)–Elixir Medical, a developer of novel cardiovascular technologies, today announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES). The study met its primary endpoint of target lesion failure (TLF) with no TLF events rep
Award Recognizes Breakthrough Innovation for INTELLISTENT®, Paving the Way for Citizens Worldwide to Receive Affordable, Cutting-Edge Cardiac Care NEW YORK , Oct. 25, 2023 /PRNewswire/ — HeartPoint Global is pleased to announce that INTELLISTENT® the company’s novel multi-lumen stent…
Non-invasive medical device developed to quickly deliver the cardiovascular insights value-based care organizations need to reduce costs and improve patient lives PASADENA, Calif., Oct. 25, 2023 /PRNewswire/ — Ventric Health, a healthcare technology company and medical device provider…
ALISO VIEJO, Calif.–(BUSINESS WIRE)– #digitalhealth–Key Findings: Patients With Aortic Stenosis (AS) Have Substantial Untreated Mortality Risk Across All Levels of AS, but AVR Remains Low
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S….
KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc., the AI-Powered Cardiac Blood Test Company, today announces the presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART® CVE blood test is highly accurate for risk assessment in patients with total blockage of a heart artery, also known as coronary Chronic Total Occlusion (CTO). Researchers from Massachusetts General Hospital (MGH) tested 241 patients with chronic total occlusion of at least one coronary (hea
CoSo Health to exclusively distribute Medinol’s most advanced coronary DES in the U.S. DENVER and TEL AVIV, Israel, Oct. 24, 2023 /PRNewswire/ — Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the…
Research affirms Implicity’s algorithm* is highly effective at identifying patterns and classifying AF episodes into medically relevant events that require clinical action CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ — Implicity, a leader in remote patient monitoring (RPM) and cardiac…
MIAMI LAKES, Fla., Oct. 24, 2023 /PRNewswire/ — Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, has announced completion of patient enrollment in SUCCESS PTA, its large post-market study with the SELUTION SLR™…
